StocksMedium•10 November 2026•
1 min read
P3 Health Partners Raises 2026 Adjusted EBITDA Guidance
Key Facts
1P3 Health Partners raised its 2026 adjusted EBITDA guidance range to $90M-$110M.
2The company is targeting $200M in value creation as part of its growth strategy.
P3 Health Partners raised its 2026 adjusted EBITDA guidance range to $90M-$110M. Seeking Alpha reported that the company is targeting $200M in value creation as part of its growth strategy, leading to the upward revision of its financial outlook for the 2026 fiscal year.
PIII closed at $4.25 on November 9, 2026, with the stock reaching a day high of $4.3 and a low of $4.01. The upward revision in guidance reflects the strategic objectives the company aims to achieve within the healthcare services sector.